IL24 and neoplasm: Such cellular structures have demonstrated improved therapeutic potential by increasing the expression of C-X-C chemokine receptor type 4, IL-24 or tumour necrosis factor-inducible gene 6 protein and prostaglandin E2 genes that promote adhesion to endothelial cells, and have tumour suppressing or anti-inflammatory properties, respectively [1,19,40,41].